In 2011, the U.S. Food and Drug Administration (FDA) approved ipilimumab (anti-CTLA-4) for the treatment of advanced melanoma, followed by pembrolizumab and nivolumab (anti-PD-1) in 2014. Here, PDCD1 is linked to melanoma.